Functional proteomic profiling of triple-negative breast cancer

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Functional proteomic profiling of triple-negative breast cancer. / Gromova, Irina; Espinoza, Jaime A.; Grauslund, Morten; Santoni-Rugiu, Eric; Talman, Maj Lis Møller; van Oostrum, Jan; Moreira, José M.A.

In: Cells, Vol. 10, No. 10, 2768, 2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Gromova, I, Espinoza, JA, Grauslund, M, Santoni-Rugiu, E, Talman, MLM, van Oostrum, J & Moreira, JMA 2021, 'Functional proteomic profiling of triple-negative breast cancer', Cells, vol. 10, no. 10, 2768. https://doi.org/10.3390/cells10102768

APA

Gromova, I., Espinoza, J. A., Grauslund, M., Santoni-Rugiu, E., Talman, M. L. M., van Oostrum, J., & Moreira, J. M. A. (2021). Functional proteomic profiling of triple-negative breast cancer. Cells, 10(10), [2768]. https://doi.org/10.3390/cells10102768

Vancouver

Gromova I, Espinoza JA, Grauslund M, Santoni-Rugiu E, Talman MLM, van Oostrum J et al. Functional proteomic profiling of triple-negative breast cancer. Cells. 2021;10(10). 2768. https://doi.org/10.3390/cells10102768

Author

Gromova, Irina ; Espinoza, Jaime A. ; Grauslund, Morten ; Santoni-Rugiu, Eric ; Talman, Maj Lis Møller ; van Oostrum, Jan ; Moreira, José M.A. / Functional proteomic profiling of triple-negative breast cancer. In: Cells. 2021 ; Vol. 10, No. 10.

Bibtex

@article{0666b61de491463aa8773f60ffc1a73d,
title = "Functional proteomic profiling of triple-negative breast cancer",
abstract = "Triple-negative breast cancer (TNBC) is a subtype of breast cancer that comprises various disease entities, all of which share a set of common features: a lack of expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, respectively. Because of their receptor status, conventional chemotherapy remains the main therapeutic option for TNBC patients. We employed a reverse phase protein array approach (RPPA), complemented by immunohistochemistry, to quantitatively profile the activation state of 84 actionable key signaling intermediates and phosphoproteins in a set of 44 TNBC samples. We performed supervised and unsupervised approaches to proteomic data analysis to identify groups of samples sharing common characteristics that could be amenable to existing therapies. We found the heterogenous activation of multiple pathways, with PI3 K/AKT/mTOR signaling being the most common event. Some specific individualized therapeutic possibilities include the expression of oncogenic KIT in association with cytokeratin 15 and Erk1/2 positive tumors, both of which may have clinical value.",
keywords = "Breast cancer, Proteomics, Reverse phase protein array, Signaling pathway profiling, Triple negative breast cancer",
author = "Irina Gromova and Espinoza, {Jaime A.} and Morten Grauslund and Eric Santoni-Rugiu and Talman, {Maj Lis M{\o}ller} and {van Oostrum}, Jan and Moreira, {Jos{\'e} M.A.}",
note = "This article belongs to the Special Issue 10th Anniversary of Cells—Advances in Cell Signaling and Regulated Cell Death.",
year = "2021",
doi = "10.3390/cells10102768",
language = "English",
volume = "10",
journal = "Cells",
issn = "2073-4409",
publisher = "MDPI AG",
number = "10",

}

RIS

TY - JOUR

T1 - Functional proteomic profiling of triple-negative breast cancer

AU - Gromova, Irina

AU - Espinoza, Jaime A.

AU - Grauslund, Morten

AU - Santoni-Rugiu, Eric

AU - Talman, Maj Lis Møller

AU - van Oostrum, Jan

AU - Moreira, José M.A.

N1 - This article belongs to the Special Issue 10th Anniversary of Cells—Advances in Cell Signaling and Regulated Cell Death.

PY - 2021

Y1 - 2021

N2 - Triple-negative breast cancer (TNBC) is a subtype of breast cancer that comprises various disease entities, all of which share a set of common features: a lack of expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, respectively. Because of their receptor status, conventional chemotherapy remains the main therapeutic option for TNBC patients. We employed a reverse phase protein array approach (RPPA), complemented by immunohistochemistry, to quantitatively profile the activation state of 84 actionable key signaling intermediates and phosphoproteins in a set of 44 TNBC samples. We performed supervised and unsupervised approaches to proteomic data analysis to identify groups of samples sharing common characteristics that could be amenable to existing therapies. We found the heterogenous activation of multiple pathways, with PI3 K/AKT/mTOR signaling being the most common event. Some specific individualized therapeutic possibilities include the expression of oncogenic KIT in association with cytokeratin 15 and Erk1/2 positive tumors, both of which may have clinical value.

AB - Triple-negative breast cancer (TNBC) is a subtype of breast cancer that comprises various disease entities, all of which share a set of common features: a lack of expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, respectively. Because of their receptor status, conventional chemotherapy remains the main therapeutic option for TNBC patients. We employed a reverse phase protein array approach (RPPA), complemented by immunohistochemistry, to quantitatively profile the activation state of 84 actionable key signaling intermediates and phosphoproteins in a set of 44 TNBC samples. We performed supervised and unsupervised approaches to proteomic data analysis to identify groups of samples sharing common characteristics that could be amenable to existing therapies. We found the heterogenous activation of multiple pathways, with PI3 K/AKT/mTOR signaling being the most common event. Some specific individualized therapeutic possibilities include the expression of oncogenic KIT in association with cytokeratin 15 and Erk1/2 positive tumors, both of which may have clinical value.

KW - Breast cancer

KW - Proteomics

KW - Reverse phase protein array

KW - Signaling pathway profiling

KW - Triple negative breast cancer

U2 - 10.3390/cells10102768

DO - 10.3390/cells10102768

M3 - Journal article

C2 - 34685748

AN - SCOPUS:85117067090

VL - 10

JO - Cells

JF - Cells

SN - 2073-4409

IS - 10

M1 - 2768

ER -

ID: 283214745